Fei Xu

机构：Ruijin Hospital, United Imaging Healthcare (China) · ORCID：0000-0002-3891-3003

发表论文 117 篇 · 总被引 1703 次 · h-index 19

代表论文

• Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial. (2024 · Journal of Clinical Oncology · 被引 14)
• 1348 Final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR + NSCLC progressed on EGFR-TKI treatment (2025 · 被引 7)
• Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial (2025 · The Lancet Oncology · 被引 6)
• Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation (2025 · Cell Reports Medicine · 被引 4)
• Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer (2025 · npj Breast Cancer · 被引 3)
• Efficacy and Safety of T‐ DXd in HER2 + and Low/Zero Metastatic BCBM : A Retrospective Multicenter Real‐World Study (2025 · Cancer Science · 被引 1)